WHAT: The Surgeon General has called VTE a major public health problem. This roundtable presentation will provide an overview of the state of VTE and its disease burden in the U.S., including prevalence and cost to the healthcare system. It will also address appropriate prophylaxis and advancing VTE management and care, and latest trends in VTE treatment.
The presentation will conclude with a Q&A session.
This presentation is sponsored by The Doctor's Channel in partnership with sanofi-aventis U.S. LLC.
WHY: VTE is a disease that encompasses both DVT and pulmonary embolism (PE). DVT occurs when a blood clot forms in one of the large veins of the upper or lower limbs, and may lead to a PE if a fragment of the blood clot breaks loose and travels to the lungs. DVT-related PE is the most common cause of preventable hospital death. DVT affects up to two million people each year in the U.S. and its primary complication, pulmonary embolism (PE), claims approximately 300,000 lives annually. More people in the U.S. die each year from DVT/PE complications than AIDS and breast cancer combined.
WHO: Alpesh Amin, M.D., Executive Director, Hospitalist Program; Medical Director, Anticoagulation Clinic; Vice Chair for Clinical Affairs & Quality Department of Medicine, University of California, Irvine
Fred Cushner, M.D., Director of the Insall Scott Kelly Institute and Associate Clinical Professor at Albert Einstein College of Medicine;
Steven Deitelzweig, M.D., Department Chairman of Hospital Medicine and Vice President of Medical Affairs at the Ochsner Medical Center;
One-on-one interviews available following the presentation
WHEN: Monday, July 13, 2009, 6:00 pm - 7:00 pm
Renaissance Boston Waterfront Hotel
606 Congress Street
Boston, Massachusetts 02210
Or via Webinar
CONTACT: RSVP to Christina Gibson by July 8, 212-367-6818 or [email protected]
/PRNewswire -- July 6/-- Current state of VTE in the U.S. and cost -- Appropriate deep vein thrombosis (DVT) prophylaxis treatment strategies -- Importance of continuity in patient care from admission through post-discharge -- Developments in VTE treatment
SOURCE sanofi-aventis U.S. LLC